Skip to main content
MyDeficiencies

Potassium chloride

Electrolyte Replacement

Also sold as Klor-Con, K-Tab.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Every other dossier in this series asks "does this drug deplete nutrient X." That question is backwards for potassium chloride, because the drug is not a depleter of a nutrient, it is the nutrient, given specifically to treat or prevent hypokalemia (most often caused by loop or thiazide diuretics, which are separate entries elsewhere in this database). There is no depletion mechanism to screen for here, and forcing one onto the page would misrepresent the drug. What this drug's own FDA labeling and the wider hyperkalemia literature actually support is a mirror-image question: given that the patient is already receiving supplemental potassium, which co-prescribed drugs, physiological states, and consumer behaviors meaningfully raise the risk of hyperkalemia, potassium excess, and which of those risks are genuinely well documented versus merely theoretical or overstated. This dossier answers that question, using the same four-tier evidence ladder and governance mapping as every other dossier in the series, repurposed explicitly for risk-of-excess rather than risk-of-deficiency. The reasoning for that structural choice is set out in full where the graded entries begin below.

oral potassium salt / electrolyte replacement · ATC A12BA · potassium · also sold as Klor-Con and K-Dur and Micro-K and generic · reviewed 2026-09-06, expanded September 10, 2026. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Potassium chloride in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
an explicit, unqualified regulatory action (a labeled contraindication, not merely a monitoring instruction) against this exact drug, verified directly against the current FDA label, with a named and plausible mechanism and no contradicting Tier A evidence found.
Orange — Moderate
a labeled, drug-specific monitoring requirement (short of a contraindication) verified directly against the current FDA label, mechanistically well characterized, real and common in ordinary practice, but bounded by dose, renal function, or comorbidity.
Yellow — Low
mechanistically plausible or context-dependent risk, resting on a professional clinical reference (Tier B) rather than a verified drug-specific cohort study, or a genuine confounder/amplifier that changes how the entries above should be read rather than a stand-alone finding of its own.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Potassium-sparing diuretics

Red — Severe

See study details

Combining potassium chloride with triamterene or amiloride is not a "monitor closely" situation, it is an explicit, unqualified contraindication on the drug's own current FDA label.

Full detail and limits

What the grade means here: an explicit, unqualified regulatory action (a labeled contraindication, not merely a monitoring instruction) against this exact drug, verified directly against the current FDA label, with a named and plausible mechanism and no contradicting Tier A evidence found. Red

Limits on what this shows

  • Key negative or null findings: None identified. No source reviewed carved out an exception or a monitored-safe-use pathway for this specific combination; the label's action is categorical, not conditional.
  • At-risk subgroups: Anyone prescribed both agents concurrently; risk rises further with any degree of renal impairment (see the renal-impairment entry below, which amplifies every entry in this dossier and is not repeated in full here).

Regulatory status

Contraindicated. Label text verified directly: "Potassium chloride is contraindicated in patients on triamterene and amiloride" and "Use with triamterene or amiloride can produce severe hyperkalemia." This is the strongest action a label can take short of a boxed warning, and it is stated for these two agents specifically, distinct from the weaker "monitor closely" instruction given for ACE inhibitors, ARBs, and spironolactone below.

Population evidence

This entry rests on one verified Tier A source, the regulatory label itself, rather than a named epidemiological cohort. An independent corroborating cohort study was sought but could not be verified this pass (see the Sources list for the specific access failures). Under this dossier's adapted bar, an unqualified regulatory contraindication is treated as qualifying evidence for RED in its own right, distinct from the two-independent-source bar used for a probabilistic finding; that substitution is stated here explicitly rather than left implicit.

Mechanism

Named and plausible. Triamterene and amiloride both block the epithelial sodium channel (ENaC) in the distal nephron, which is the same channel whose activity normally drives distal potassium secretion. Adding exogenous potassium on top of a diuretic that is already suppressing the kidney's main route of potassium disposal removes the patient's principal compensatory mechanism at the same time the potassium load increases.

Counter-evidence held on record

None found. This is a categorical label instruction rather than a graded probabilistic finding, so there is no "well-tolerated in practice" counter-evidence to weigh against it the way there is for the ORANGE entries below. Framing caution for the consumer surface Do not generalize this entry to every potassium-sparing diuretic. Spironolactone and eplerenone are potassium-sparing by a different mechanism (aldosterone-receptor blockade) and are addressed separately below under a "monitor closely" label instruction, not a contraindication. Collapsing the two into one blanket "avoid all potassium-sparing diuretics" message would misstate what the label actually says.

ACE inhibitors, ARBs, and spironolactone

Orange — Moderate

See study details

The label requires close potassium monitoring, not avoidance, when potassium chloride is combined with an ACE inhibitor, an ARB, or spironolactone, because all three blunt the same aldosterone-driven excretory pathway the kidney would otherwise use to clear the added potassium.

Full detail and limits

What the grade means here: a labeled, drug-specific monitoring requirement (short of a contraindication) verified directly against the current FDA label, mechanistically well characterized, real and common in ordinary practice, but bounded by dose, renal function, or comorbidity. Orange

Limits on what this shows

  • Key negative or null findings: A professional clinical reference reviewed here states that in chronic kidney disease specifically, hyperkalemia remains uncommon until glomerular filtration rate falls below roughly 10 to 15 mL/min, "unless dietary or IV potassium intake is excessive." That is a real, bounded protective threshold, not merely a theoretical one, and it means preserved renal function is doing real work in keeping this combination safe for most patients who receive it under monitoring.
  • At-risk subgroups: Reduced eGFR, older adults, diabetes, heart failure, and concurrent use of an NSAID or a second RAAS-axis drug on top of the first.

Regulatory status

Labeled warning requiring close monitoring, verified directly against the current FDA label: "Closely monitor potassium in patients on concomitant RAAS inhibitors," with ACE inhibitors, ARBs, and spironolactone named together under that instruction. This is a materially weaker label action than the triamterene/amiloride contraindication above.

Population evidence

No potassium-chloride-specific interventional or observational cohort with this drug directly in the study population was independently verified this pass. A landmark, frequently cited epidemiological study on this exact question exists in the literature (see Sources, item 7); its title, authors, journal, and year were confirmed through a bibliographic database, but its full text could not be opened despite three separate access attempts, so no statistic, rate, or sample size from it is used anywhere in this entry. The entry is therefore graded ORANGE on the strength of the regulatory label and named mechanism alone, not RED, which under this dossier's own bar would require a verified corroborating cohort.

Mechanism

Named and plausible. ACE inhibitors and ARBs reduce angiotensin-II-driven aldosterone release; spironolactone directly blocks the aldosterone receptor. Aldosterone is the primary hormonal driver of distal-nephron potassium secretion, so all three drugs blunt the kidney's ability to excrete an added potassium load by the same downstream pathway, even though they act at different points upstream of it.

Counter-evidence held on record

This exact combination is also standard, guideline-directed, and often deliberately co-prescribed in heart failure and hypertension management, where diuretic-induced hypokalemia is common and low-dose RAAS-inhibitor therapy is simultaneously indicated for cardiovascular benefit. The combination is not inherently dangerous under routine laboratory monitoring and preserved renal function; it becomes dangerous specifically when monitoring lapses, renal function declines, or additional risk factors stack on top of it. Framing caution for the consumer surface This entry must never read as "avoid ACE inhibitors, ARBs, or spironolactone if you take a potassium supplement." Both classes are frequently and appropriately prescribed together, under monitoring, for good reason. The entry names a monitoring requirement grounded in the drug's own label, not a general incompatibility.

NSAIDs

Orange — Moderate

See study details

Concomitant NSAID use requires close potassium monitoring per the label, because NSAIDs blunt the renal prostaglandin pathway that supports potassium excretion, with the effect most pronounced when renal perfusion is already reduced.

Full detail and limits

What the grade means here: a labeled, drug-specific monitoring requirement (short of a contraindication) verified directly against the current FDA label, mechanistically well characterized, real and common in ordinary practice, but bounded by dose, renal function, or comorbidity. Orange

Limits on what this shows

  • Key negative or null findings: The effect is typically small and clinically silent in a person with normal renal function taking an NSAID occasionally (for example, a few doses for a headache); the label's monitoring language applies most clearly to regular or chronic NSAID use, not incidental use.
  • At-risk subgroups: Renal impairment, volume depletion, concurrent RAAS inhibitor or potassium-sparing diuretic, older adults, and chronic or high-dose NSAID use rather than occasional use.

Regulatory status

Labeled warning requiring close monitoring, verified directly against the current FDA label alongside the RAAS-inhibitor instruction above: "Closely monitor potassium in patients on concomitant NSAIDs."

Population evidence

No potassium-chloride-specific cohort with this drug directly studied was independently verified this pass. A class-level review of NSAID-associated electrolyte disturbances was located through a secondary citation, but its full text could not be opened this pass (see Sources, item 9) and no statistic from it is used here. As with the entry above, this rests on the verified regulatory label and named mechanism rather than a verified cohort study, which is why it is graded ORANGE rather than RED.

Mechanism

Named and plausible. Renal prostaglandins normally support afferent-arteriole vasodilation and distal potassium secretion; NSAIDs, through COX inhibition, reduce prostaglandin synthesis and blunt this pathway, an effect that is most pronounced when there is coexisting volume depletion, renal impairment, or additional RAAS-axis blockade from another drug.

Counter-evidence held on record

Occasional over-the-counter NSAID use in a person with normal renal function and no other risk factor on this list carries a materially lower risk than the entry title alone conveys; the risk is use-pattern- and comorbidity-dependent, not a fixed property of ever taking an NSAID. Framing caution for the consumer surface This is not "never take ibuprofen." It is "regular or high-dose NSAID use is a reason your prescriber may want to check your potassium more often, especially alongside the drugs named above."

Renal impairment

Yellow — Low

See study details

Reduced kidney function is not itself a drug interaction; it is the single largest amplifier of every hyperkalemia risk graded above, and none of those entries should be read as a fixed, renal-function-independent probability.

Full detail and limits

What the grade means here: mechanistically plausible or context-dependent risk, resting on a professional clinical reference (Tier B) rather than a verified drug-specific cohort study, or a genuine confounder/amplifier that changes how the entries above should be read rather than a stand-alone finding of its own. Yellow

Limits on what this shows

  • Key negative or null findings: Mild-to-moderate chronic kidney disease alone, without a superimposed drug effect or an excessive potassium load, does not reliably produce hyperkalemia by the same reference's own threshold framing.
  • At-risk subgroups: Chronic kidney disease stage 4 to 5, acute kidney injury, dehydration or volume depletion, and older adults with age-related decline in glomerular filtration rate.

Regulatory status

Named as a risk factor throughout the potassium chloride label's warnings section (Tier A, drug-specific) and discussed independently in a professional clinical reference on hyperkalemia (Tier B, class-level).

Population evidence

A professional reference states that sustained hyperkalemia "usually implies diminished renal potassium excretion," and that in chronic kidney disease specifically, hyperkalemia remains uncommon until glomerular filtration rate falls below roughly 10 to 15 mL/min, unless intake is excessive. That is a directional, threshold-framed statement from a secondary clinical reference, not an incidence figure from a named primary cohort, which is why it is graded YELLOW rather than promoted higher.

Mechanism

The kidney is the dominant route of potassium excretion. As glomerular filtration falls, the distal nephron's capacity to excrete an acute or chronic potassium load falls with it. The drugs graded RED and ORANGE above all act on that same excretory pathway, so their effects compound with reduced renal reserve rather than acting independently of it.

Counter-evidence held on record

Many people with mild renal impairment tolerate maintenance-dose potassium chloride for years without incident under routine monitoring; this entry is a confounder-and-amplifier flag, not a standalone contraindication for anyone with any degree of reduced kidney function. Framing caution for the consumer surface Present this only as "your prescriber will want to know about your kidney function," never as a specific risk percentage or as a reason to stop a prescribed potassium regimen without medical guidance. No drug-specific cohort quantifying the exact size of this amplification was verified this pass.

Magnesium status can make potassium repletion fail, not the reverse

Yellow — Low

See study details

Coexisting magnesium deficiency can make hypokalemia resistant to potassium chloride treatment by sustaining renal potassium wasting; this is magnesium status affecting the success of potassium therapy, not evidence that potassium chloride itself depletes magnesium.

Full detail and limits

What the grade means here: mechanistically plausible or context-dependent risk, resting on a professional clinical reference (Tier B) rather than a verified drug-specific cohort study, or a genuine confounder/amplifier that changes how the entries above should be read rather than a stand-alone finding of its own. Yellow

Limits on what this shows

  • Key negative or null findings: Not every case of hypokalemia involves magnesium deficiency; this pathway is only clinically relevant when hypokalemia fails to correct despite dosing that should otherwise be adequate.
  • At-risk subgroups: Patients on loop or thiazide diuretics, which waste potassium and magnesium together, chronic diarrhea, alcohol use disorder, and chronic proton pump inhibitor use.

Regulatory status

Not addressed in the potassium chloride label itself; sourced from a professional clinical reference rather than drug-specific regulatory language.

Population evidence

A professional reference states: "When hypokalemia occurs with hypomagnesemia, both the potassium and magnesium deficiencies must be corrected to stop ongoing renal potassium wasting." This is a mechanistic and clinical-practice statement from a secondary reference, not a specific trial's effect size, which caps this entry at YELLOW.

Mechanism

Intracellular magnesium normally inhibits the ROMK potassium channel in the distal nephron. When magnesium is low, that inhibition is lost and the kidney continues to waste potassium into the urine even while oral or IV potassium is being given, which is what makes the hypokalemia appear "refractory" to an otherwise adequate potassium dose.

Counter-evidence held on record

No counter-finding was located that contradicts the magnesium-potassium relationship itself; the caveat here is one of scope, this mechanism explains only the refractory subset of hypokalemia cases, not hypokalemia in general. Framing caution for the consumer surface This is not a reason to add a magnesium supplement without testing. It is a reason a clinician may check serum magnesium when potassium chloride alone is not correcting hypokalemia as expected. No magnesium dose is recommended anywhere in this dossier.

GI ulceration and stricture

Not graded — disclosed evidence gap

See study details

This dossier's tiers grade hyperkalemia-interaction risk only. The documented risk that solid oral potassium chloride can injure the GI mucosa on prolonged contact is real, well described, and formulation-specific, but it is a mechanical injury, not an electrolyte or nutrient-status finding, and grading it on the same scale as the entries above would misrepresent both.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Not graded

Regulatory status

The extended-release tablet label warns of ulcerative and/or stenotic GI lesions with prolonged mucosal contact and instructs discontinuation if severe vomiting, abdominal pain, distension, or GI bleeding occurs. Directly compared against this, the oral-solution label from the same drug carries no ulceration or stenosis language at all, only a general caution about irritation if the solution is taken undiluted.

Why it is excluded from the tier ladder above

The mechanism is local and mechanical (prolonged mucosal contact with a concentrated bolus of solid or slow-dissolving material), not systemic or electrolyte-driven, and it does not track with serum potassium, renal function, or any of the drug interactions graded above. Filing it under RED, ORANGE, or YELLOW would conflate two analytically distinct hazards this dossier is required to keep separate.

Where it is actually addressed

In full, in the monitoring panel and safety review below, including the specific administration steps (taking with meals and a full glass of water, not crushing or chewing extended-release tablets, using a liquid formulation for anyone with dysphagia) that the label itself gives to reduce this risk.

Counter-evidence held on record

All four tiers above (RED, ORANGE, YELLOW, WHITE further below) are populated in this dossier; none were empty. This entry exists instead to make an intentional structural exclusion visible, per the same principle that would require printing an empty tier with its reasoning if one had occurred.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

General tissue-injury physiology makes it mechanistically plausible that the mucosal lesion this drug's own label already documents carries local mitochondrial stress at the injury site; no study has measured mitochondrial parameters in that tissue, and nothing here suggests a systemic effect.

Full detail, limits and 3 references

What the grade means here: mechanistically plausible or context-dependent risk, resting on a professional clinical reference (Tier B) rather than a verified drug-specific cohort study, or a genuine confounder/amplifier that changes how the entries above should be read rather than a stand-alone finding of its own. Yellow

Limits on what this shows

  • Key negative or null findings: None identified in either direction. No source reviewed reported normal mitochondrial parameters in this context either; the absence of data is recorded as an absence, not as reassurance.
  • At-risk subgroups: The same population already named for the underlying GI injury risk: prolonged use of solid extended-release tablets or capsules, pre-existing GI strictures or dysmotility, and dysphagia, per the existing label warning documented above.
  • Dose/duration: Not established. The label frames the injury risk around prolonged mucosal contact of solid dosage forms rather than a specific dose or duration threshold, and no duration figure could be verified this pass. No dose or duration recommendation is made here.

Regulatory status

The extended-release tablet label documents ulcerative and/or stenotic GI lesions from prolonged mucosal contact (Tier A, drug-specific, already verified in the pharmacokinetic basis above). The label names the lesion; it does not name a mitochondrial mechanism for it, and none is claimed here as labeled.

Population evidence

No study located this pass measured mitochondrial membrane potential, ATP content, or electron transport chain activity in tissue exposed to potassium chloride, or in any patient on this drug. Three case-series/report sources on KCl-induced small bowel ulceration were located and their title, authors, journal, and year confirmed via PubMed search-listing metadata (Ashby et al., 1965, PMID 5850690; Buchan and Houston, 1965, PMID 14232192; Leijonmarck and Räf, 1985, a retrospective series of 22 cases, PMID 4013604); the individual abstract pages returned bot-verification challenges on every attempt, so no mechanism statement from within them is quoted or relied on here.

Mechanism

Not established specifically for potassium chloride. General ischemic and necrotic tissue injury, from any cause, is understood in broader cell-injury physiology to involve mitochondrial permeability transition and impaired oxidative phosphorylation as part of the cell-death cascade. Applying that general principle to the specific lesion this drug's label documents is mechanistically plausible, but it rests on general pathophysiology rather than a potassium-chloride-specific mechanistic study, which is stated here explicitly rather than left to read as though a dedicated study exists. This is distinct from, and must not be confused with, potassium's own inherent physiological role as a substrate of the Na + /K + -ATPase pump; that role belongs to the nutrient's normal biology, not to evidence that the drug burdens mitochondrial function.

Counter-evidence held on record

None found. No potassium-chloride-specific mitochondrial study exists to weigh either direction. Framing caution for the consumer surface This must never read as "potassium chloride damages your mitochondria" as a general or systemic claim. It concerns a hypothetical, tissue-level plausibility confined to documented mucosal injury sites in solid-dosage-form use, and is not a basis for any supplement, dose, or formulation change made outside a prescriber's guidance.

  • Ashby EC, et al. Small-bowel ulceration induced by potassium chloride. British Medical Journal, 1965. — Located via PubMed search-listing metadata (PMID 5850690) for the September 10, 2026 expansion. Named for completeness as a drug-specific historical case source for the GI-mucosal-injury anchor used in the mitochondrial burden, oxidative stress, and gut microbiome risk entries above.Full text and abstract not verified this pass: the individual PubMed abstract page returned a bot-verification challenge on every attempt. No statistic or mechanism statement from this source is quoted anywhere in this dossier.
  • Buchan JG, Houston JR. Small bowel ulceration associated with enteric-coated potassium chloride and hydrochlorothiazide. Canadian Medical Association Journal, 1965. — Located via PubMed search-listing metadata (PMID 14232192) for the September 10, 2026 expansion. Named for completeness alongside the Ashby source above.Full text not independently opened this pass; only the search-listing metadata (three cases of intestinal obstruction due to solitary localized ulceration, inflammation, and stenosis) was reviewed. No statistic beyond that listing snippet is used anywhere in this dossier.
  • Leijonmarck CE, Räf L. Ulceration of the small intestine due to slow-release potassium chloride tablets. Acta Chirurgica Scandinavica, 1985. — Located via PubMed search-listing metadata (PMID 4013604) for the September 10, 2026 expansion. A retrospective series of 22 cases; named for completeness for the GI-mucosal-injury anchor above.Full text not independently opened this pass. No statistic beyond the case count already stated is used anywhere in this dossier.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

Mucosal ulceration from any cause commonly involves free-radical-mediated tissue damage as part of the injury cascade; extending that general principle to the KCl-specific lesion this drug's label documents is plausible, but no study has measured oxidative stress markers in that tissue or in patients on this drug.

Full detail and limits

What the grade means here: mechanistically plausible or context-dependent risk, resting on a professional clinical reference (Tier B) rather than a verified drug-specific cohort study, or a genuine confounder/amplifier that changes how the entries above should be read rather than a stand-alone finding of its own. Yellow

Limits on what this shows

  • Key negative or null findings: None identified for this drug in either direction.
  • At-risk subgroups: Same population as the underlying GI injury risk. Concurrent regular NSAID use (already graded ORANGE above for its separate hyperkalemia-monitoring reason) independently carries its own, mechanistically distinct GI-mucosal injury pathway via COX inhibition, which could theoretically compound local injury with solid-dosage potassium chloride; no combined-exposure study was verified this pass, so this is flagged as a consideration, not quantified as a finding.
  • Dose/duration: Not established, for the same reason given in the mitochondrial-burden entry above. No dose or duration recommendation is made here.

Regulatory status

Same Tier A label anchor as the mitochondrial-burden entry above: documented ulcerative and/or stenotic GI lesions from prolonged mucosal contact. The label carries no oxidative-stress language.

Population evidence

No potassium-chloride-specific study located this pass measured oxidative stress biomarkers (for example malondialdehyde, 8-OHdG, or glutathione status) in association with this drug. A 2025 rodent study on dietary potassium supplementation and oxidative stress in a hypertension model was located via search-listing metadata; it addresses systemic, blood-pressure-linked effects of dietary potassium intake broadly, a different question from the localized mucosal-injury mechanism graded here, and its full text was not opened this pass. It is recorded here to document that it was found and actively excluded as off-target, not used as supporting evidence, and it should be noted that its apparent direction (potassium intake associated with reduced oxidative markers in that model) runs opposite to the local-injury plausibility graded here, which is a direction check performed deliberately rather than an oversight.

Mechanism

General principle, not a potassium-chloride-specific mechanistic study: mucosal ulceration or necrosis of any etiology commonly involves oxidative or free-radical-mediated tissue injury (well characterized for NSAID-associated GI injury, for example). Applying this to the lesion documented on this drug's own label is mechanistically plausible but unverified for this specific drug.

Counter-evidence held on record

The 2025 dietary-potassium rodent study noted above points, if anything, toward a protective association between potassium intake and oxidative markers in a different physiological context; it is not counter-evidence to this specific local-injury entry, but it is recorded so the entry is not read as though all potassium-oxidative-stress literature points one direction. Framing caution for the consumer surface Not a systemic oxidative-stress claim, and not a basis for antioxidant supplementation of any kind or dose.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No mechanistic, class-level, or circulating-claim evidence connects potassium chloride supplementation to copper absorption or copper status; this is a gap, not a clean bill of health.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Key negative or null findings: None available; absence of data is recorded as absence, not as a null result.
  • At-risk subgroups: None identified from any source reviewed.
  • Dose/duration: No dose or duration data exists to report; none is recommended here.

Regulatory status

Not addressed in the potassium chloride label. The NIH Office of Dietary Supplements copper fact sheet, reviewed directly, does not mention potassium or potassium chloride anywhere in its interactions content.

Population evidence

None located this pass in any source reviewed.

Mechanism

None named. For comparison, zinc's interference with copper absorption is well documented (the same NIH fact sheet states that high zinc intake "can interfere with copper absorption," the basis for zinc's own upper intake level), but potassium chloride was not named alongside zinc in that source or any other reviewed, and that zinc-specific mechanism is not extrapolated onto potassium here without direct evidence.

Counter-evidence held on record

This gap must not be read as reassurance that no interaction exists between potassium chloride and copper status; it means no qualifying evidence was found on either side this pass.

Iron

Not graded — disclosed evidence gap

See study details

No mechanistic, class-level, or circulating-claim evidence connects potassium chloride supplementation to iron absorption or iron status; this is a gap, not a clean bill of health.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Key negative or null findings: None available; absence of data is recorded as absence.
  • At-risk subgroups: None identified from any source reviewed.
  • Dose/duration: No dose or duration data exists to report; none is recommended here.

Regulatory status

Not addressed in the potassium chloride label. The NIH Office of Dietary Supplements iron fact sheet, reviewed directly, does not mention potassium or potassium chloride anywhere in its interactions content; that fact sheet discusses calcium, levodopa, levothyroxine, and proton pump inhibitors as interactions, not potassium.

Population evidence

None located this pass in any source reviewed.

Mechanism

None named. Potassium chloride's own label does not describe a gastric-pH or transporter-competition effect of the kind documented for other iron-interacting agents, so no plausible absorption-interference pathway was identified to extrapolate from.

Counter-evidence held on record

The documented GI mucosal injury risk (see the Yellow section above) concerns local ulceration, not blood loss as a routine finding; a hypothetical bleeding-to-anemia-to-iron-status pathway was considered and deliberately not graded here, because filing a rare complication's downstream clinical outcome as an iron-status finding would misfile a clinical outcome as a nutrient-deficiency claim.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

The same Tier A, drug-specific mucosal injury already documented on this drug's label is a recognized general route to local barrier disruption and altered luminal ecology; no study has measured gut microbiome composition or function in patients on potassium chloride.

Full detail and limits

What the grade means here: mechanistically plausible or context-dependent risk, resting on a professional clinical reference (Tier B) rather than a verified drug-specific cohort study, or a genuine confounder/amplifier that changes how the entries above should be read rather than a stand-alone finding of its own. Yellow

Limits on what this shows

  • Key negative or null findings: None identified; no study has looked, so none has found a normal or unaffected microbiome either.
  • At-risk subgroups: Same population as the underlying GI injury risk: prolonged solid extended-release use, pre-existing GI strictures or dysmotility, dysphagia.
  • Dose/duration: Not established, for the same reason given above. No dose or duration recommendation is made here.

Regulatory status

Same Tier A label anchor as the two entries above. The label does not address microbiome or intestinal flora at all.

Population evidence

No human or animal study located this pass measured intestinal microbiota composition, diversity, or function in association with potassium chloride exposure. A 2019 food-science study on potassium chloride as a partial sodium-chloride substitute in cheese production, examining microbial community effects in a fermentation/food-matrix context (PMID not applicable, located via PubMed search-listing metadata), was reviewed and excluded as not applicable evidence: it concerns a food product's microbiology, not the human gut, and is recorded here only to document that it was found and set aside rather than silently omitted.

Mechanism

General principle, not a potassium-chloride-specific study: mucosal ulceration and altered local luminal chemistry are recognized contributors to local dysbiosis in the broader GI literature (barrier disruption, altered nutrient and bile-acid availability at a lesion site). Applying this to the specific lesion documented on this drug's label is mechanistically plausible but not demonstrated for potassium chloride by any microbiome study identified this pass.

Counter-evidence held on record

None found for this drug specifically. Framing caution for the consumer surface Not a general "potassium harms gut bacteria" claim, and not a basis for probiotic or dietary recommendations. Concerns a local, injury-site-associated plausibility only.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No mechanistic, class-level, or circulating-claim evidence connects potassium chloride supplementation, as distinct from the drug's already-graded hyperkalemia risk, to oxygen delivery or utilization.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Key negative or null findings: None available.
  • At-risk subgroups: None identified from any source reviewed for this specific parameter.
  • Dose/duration: No dose or duration data exists to report; none is recommended here.

Regulatory status

Not addressed in the potassium chloride label beyond the hyperkalemia warnings already graded RED and ORANGE above.

Population evidence

None located this pass on potassium chloride and hemoglobin oxygen affinity, red cell 2,3-DPG, or tissue oxygen utilization. Searches returned only unrelated material (red cell cryopreservation using inosine, and phosphorus repletion in diabetic ketoacidosis), neither of which concerns potassium.

Mechanism

None named. Two tempting but rejected pathways were actively considered and excluded rather than silently omitted. First, severe hyperkalemia's known cardiac and neuromuscular membrane effects are this drug's own already-graded excess-risk mechanism (see the Red and Orange entries above); refiling that same clinical effect here as a new "oxygen delivery" finding would misfile the drug's own known effect as if it were a separate nutrient-status finding. Second, GI bleeding from the drug's mucosal-injury risk could in principle cause anemia and secondarily reduce oxygen-carrying capacity, but this is a clinical outcome of a rare complication, not a measured drug effect on oxygen delivery, and filing it here would misfile a clinical outcome as though it were a direct finding.

Counter-evidence held on record

This gap must not be read as reassurance; it means no qualifying evidence, and no rejected consumer claim, were found this pass.

ATP production

Not graded — disclosed evidence gap

See study details

No evidence found this pass shows potassium chloride supplementation itself burdening ATP production; potassium's own role as a substrate of the Na + /K + -ATPase pump is the nutrient's inherent physiology, not a drug effect, and is excluded from this entry on that basis.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Key negative or null findings: None available.
  • At-risk subgroups: None identified from any source reviewed for this specific parameter.
  • Dose/duration: No dose or duration data exists to report; none is recommended here.

Regulatory status

Not addressed in the potassium chloride label.

Population evidence

None located this pass connecting potassium chloride supplementation, as opposed to potassium's normal physiological role, to any measure of cellular ATP production or energetic burden.

Mechanism

None named for a drug effect. Potassium is directly involved in the Na + /K + -ATPase pump and cellular energetics broadly, but that is potassium's own physiological role, present whether the potassium is dietary or supplemental, and is deliberately not filed here as evidence that the drug burdens ATP production; only genuine evidence of a supplementation-specific burden would qualify, and none was found. Magnesium is a cofactor in ATP-dependent enzymes and mitochondrial function generally, and magnesium-potassium interplay is already graded YELLOW above (magnesium status affecting potassium therapy); no new evidence this pass extended that relationship to a potassium-chloride-caused magnesium or ATP burden running the opposite direction, so it is not re-derived here.

Counter-evidence held on record

This gap must not be read as reassurance; it means no qualifying evidence, and no rejected consumer claim, were found this pass.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • "Potassium is a healthy mineral most people don't get enough of, so more from a supplement or a potassium-based salt substitute is safe for anyone."

    Where it comes from: General wellness and DASH-diet-adjacent messaging that emphasizes population-level under-intake of dietary potassium.

    Why it fails: True for dietary potassium in someone with normal kidney function, where the kidney readily excretes excess. Not true once the source is a concentrated supplement or salt substitute, and not true at all for people with kidney disease or on the drugs graded RED or ORANGE above; a fact sheet reviewed here states plainly that "very high amounts of potassium supplements or salt substitutes containing potassium could exceed the kidney's capacity to excrete potassium, causing acute hyperkalemia even in healthy individuals," and separately advises that people with kidney disease or on certain medications should consult a clinician before using potassium-based salt substitutes.

  • "An over-the-counter potassium tablet is a fine substitute for a prescribed potassium chloride regimen."

    Where it comes from: Consumer supplement marketing and casual assumptions that any potassium pill is interchangeable with any other.

    Why it fails: Factually reversed by the regulator's own history with this exact chemical. A source reviewed here states that FDA has ruled oral drug products containing more than 99 mg of potassium chloride unsafe outside prescription control because of an association with small-bowel lesions, which is why OTC potassium-only products are capped at 99 mg, roughly one-tenth to one-fortieth of a typical prescribed daily dose (782 to 3,910 mg elemental potassium across the labeled 20 to 100 mEq/day range). The two products are deliberately not equivalent, by regulatory design.

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Lab monitoring

    Serum potassium

    Checked at baseline and periodically during therapy, and again whenever a dose changes or a RAAS inhibitor, potassium-sparing diuretic, or regular NSAID is started or stopped. This is the parameter the whole therapy is titrated against; nothing in this dossier substitutes for it.

  • Lab monitoring

    Renal function (eGFR / creatinine)

    The dominant amplifier of every interaction graded above. A change in renal function changes the risk calculus for every entry in this dossier, not just one of them.

  • Refractory hypokalemia

    Serum magnesium

    Worth checking if hypokalemia is not correcting as expected on an otherwise adequate potassium dose; sustained renal potassium wasting driven by low magnesium is a recognized reason for apparent treatment failure.

  • GI mechanical injury

    Abdominal pain, distension, GI bleeding

    The label instructs discontinuing solid-dosage-form potassium chloride and seeking care if severe vomiting, abdominal pain, distension, or bleeding occurs. This is the formulation-specific mechanical risk kept separate from the hyperkalemia entries above.

  • Administration

    Take with food, full glass of water

    Per label: reduces gastric irritation and mucosal contact time. Extended-release tablets should be swallowed whole, never crushed, chewed, or sucked; the oral solution should be diluted with at least 4 ounces of cold water before drinking.

  • Formulation choice

    Liquid formulations for dysphagia

    The label specifically directs a switch to a liquid formulation for patients who have difficulty swallowing solid dosage forms, precisely because prolonged mucosal contact is the mechanism of the GI injury risk.

  • Consumer behavior

    Salt substitute awareness

    Many "no salt" and "lite salt" products are potassium chloride by another name, at meaningfully large doses (roughly 440 to 2,800 mg of potassium per teaspoon by one source's estimate). Anyone already on a prescribed potassium regimen, a RAAS inhibitor, a potassium-sparing diuretic, or with reduced kidney function should not add these without telling their prescriber, since the potassium load stacks with the prescribed dose.

  • Consumer behavior

    Not a substitute for OTC potassium products

    OTC potassium-only tablets are capped at 99 mg per the FDA's own historical rule and are not an equivalent, interchangeable, or scalable substitute for a prescribed regimen; the two are regulated differently on purpose.

  • Medication reconciliation

    Flag every new prescription and OTC addition

    Any new ACE inhibitor, ARB, spironolactone, potassium-sparing diuretic, or regular NSAID use (including OTC ibuprofen or naproxen) is a reason to mention the existing potassium chloride regimen to whoever is prescribing it, and vice versa.

All references used above
  1. Potassium Chloride Extended-Release Tablets, USP (Strides Pharma Science Limited) — FDA-approved prescribing information, accessed via DailyMed. Used for: indications, clinical pharmacology (absorption, distribution, elimination), contraindications, hyperkalemia warnings, GI warnings, dosing.
  2. Potassium Chloride Tablet, Film Coated, Extended Release (Preferred Pharmaceuticals Inc.) — FDA-approved prescribing information, accessed via DailyMed. Used for: contraindications (triamterene/amiloride), GI ulceration/stenosis warning language, RAAS-inhibitor and NSAID monitoring language, potassium distribution figures.
  3. Potassium Chloride (Potassium Chloride Oral) Solution (Cardinal Health 107, LLC) — FDA-approved prescribing information, accessed via DailyMed. Used for: confirming the oral-solution label carries no ulceration/stenosis warning, dosing, dilution instructions, contraindications and monitoring language for this formulation.
  4. National Institutes of Health, Office of Dietary Supplements. Potassium: Fact Sheet for Health Professionals. — Used for: no established UL and the reasoning behind that, AI values, the healthy-kidney-food-vs-supplement distinction, salt substitute potassium content and warning, the 99 mg OTC potassium cap and its regulatory origin, at-risk populations for hyperkalemia.
  5. Merck Manual, Professional Version. Hyperkalemia. — Tier B professional clinical reference (class-level, not stratified to potassium chloride specifically). Used for: list of drug causes of reduced potassium excretion, and the GFR threshold framing for renal impairment as a risk amplifier.
  6. Merck Manual, Professional Version. Hypokalemia. — Tier B professional clinical reference. Used for: the magnesium-potassium relationship in refractory hypokalemia.
  7. National Library of Medicine, RxClass. ATC classification lookup for potassium chloride. — Used to verify the ATC class A12BA (potassium) at the classification-group level; the precise seven-character substance code was not independently re-derived at that granularity this pass, so the chip above states the verified class-level code only.
  8. Juurlink DN, Mamdani M, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine, 2004. — Named for completeness as the landmark epidemiological study most directly relevant to the ACE-inhibitor/ARB/spironolactone entry above.Full text not verified this pass: the PubMed abstract page returned only a bot-verification challenge, the NEJM article page returned HTTP 403, and the Europe PMC API returned HTTP 429 (rate-limited) on every retry attempted. No statistic, sample size, or effect estimate from this paper is cited anywhere in this dossier.
  9. Kovesdy CP. Management of Hyperkalemia: An Update for the Internist. American Journal of Medicine, 2015;128(12):1281-7. — Located via a secondary citation (Wikipedia's reference list for hyperkalemia); named for completeness only.Full text not verified this pass: the publisher page returned no retrievable article text. No statistic from this paper is cited anywhere in this dossier.
  10. Kim S, Joo KW. Electrolyte and Acid-Base Disturbances Associated with Non-Steroidal Anti-Inflammatory Drugs. Electrolytes & Blood Pressure, 2007;5(2):116-125. — Located via a secondary citation; named for completeness as a class-level source relevant to the NSAID entry above.Full text not verified this pass: the DOI resolver target was blocked by the site's robots.txt rules. No statistic from this paper is cited anywhere in this dossier.
  11. Ashby EC, et al. Small-bowel ulceration induced by potassium chloride. British Medical Journal, 1965. — Located via PubMed search-listing metadata (PMID 5850690) for the September 10, 2026 expansion. Named for completeness as a drug-specific historical case source for the GI-mucosal-injury anchor used in the mitochondrial burden, oxidative stress, and gut microbiome risk entries above.Full text and abstract not verified this pass: the individual PubMed abstract page returned a bot-verification challenge on every attempt. No statistic or mechanism statement from this source is quoted anywhere in this dossier.
  12. Buchan JG, Houston JR. Small bowel ulceration associated with enteric-coated potassium chloride and hydrochlorothiazide. Canadian Medical Association Journal, 1965. — Located via PubMed search-listing metadata (PMID 14232192) for the September 10, 2026 expansion. Named for completeness alongside the Ashby source above.Full text not independently opened this pass; only the search-listing metadata (three cases of intestinal obstruction due to solitary localized ulceration, inflammation, and stenosis) was reviewed. No statistic beyond that listing snippet is used anywhere in this dossier.
  13. Leijonmarck CE, Räf L. Ulceration of the small intestine due to slow-release potassium chloride tablets. Acta Chirurgica Scandinavica, 1985. — Located via PubMed search-listing metadata (PMID 4013604) for the September 10, 2026 expansion. A retrospective series of 22 cases; named for completeness for the GI-mucosal-injury anchor above.Full text not independently opened this pass. No statistic beyond the case count already stated is used anywhere in this dossier.
  14. Scarpignato C, Bjarnason I. Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. Current Gastroenterology Reports, 2019. — Located via PubMed search-listing metadata (PMID 31720893) for the September 10, 2026 expansion. A class-level review naming supplement-induced (including potassium chloride) small bowel ulceration, stenosis, and perforation per the search-listing snippet.Full text not verified this pass: the individual PubMed abstract page returned an HTTP 429 rate-limit error on one attempt and a bot-verification challenge on a second. No statistic or mechanism statement beyond the search-listing snippet is used anywhere in this dossier.
  15. National Institutes of Health, Office of Dietary Supplements. Copper: Fact Sheet for Health Professionals. — Reviewed directly for the September 10, 2026 expansion. Used to confirm the absence of any documented potassium or potassium-chloride interaction with copper absorption or status, and as the source for the zinc-copper absorption-competition comparator used in the Copper entry above.
  16. National Institutes of Health, Office of Dietary Supplements. Iron: Fact Sheet for Health Professionals. — Reviewed directly for the September 10, 2026 expansion. Used to confirm the absence of any documented potassium or potassium-chloride interaction with iron absorption or status.
  17. Examine.com. Potassium. — Independent supplement-evidence reference, reviewed directly for the September 10, 2026 claim audit. Used to check for circulating consumer claims about potassium or potassium chloride affecting mitochondria, oxidative stress, copper or iron status, gut microbiome, oxygen delivery/utilization, or ATP production; none were found on this page.